Lilly hits record high after Mounjaro fuels forecast raise, rival data
By Bhanvi Satija and Mariam Sunny (Reuters) -Eli Lilly on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares soaring 18% to a record high also helped by positive data from a rival drug. The U.S. company’s shares…
